

CN Bio announces opening of new Biosafety Level 3 facility

Unveils plans to enhance research capabilities in new UK facility

Oxford and Welwyn Garden City, UK, 12th January 2015: CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK. The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes based on the company's proprietary *in vitro* models of viral liver infection, including Hepatitis B. The new facility will additionally comprise BSL-2 laboratories, an engineering laboratory and office space.

New models pave the way to a cure

"The development by CN Bio of Quantum-B®, a human *in vitro* full viral lifecycle model of Hepatitis B, has come at a time of a vast acceleration of efforts by researchers and the pharmaceutical industry to develop a cure for the disease" commented CN Bio's Chief Operating Officer, Dr Emma Sceats. "The new facility at BioPark Welwyn Garden City will enable expansion of our drug discovery alliances with pharma and biotech partners and provide additional capacity for development of the company's other advanced *in vitro* liver models, including novel immune-competent models of liver infection".

Research and development will transfer to Welwyn Garden City from today with the closure of CN Bio's Oxford facility on 27 February, 2015. All positions will transfer to the new facility and recruitment of additional scientific staff will continue into early 2015 to ensure the company is positioned to fulfil growing demand from our partners and research sponsors.

For more information about CN Bio's new Welwyn Garden City location and access to the company's BSL-3 facilities via external R&D and partnering opportunities please contact CN Bio's Director of Licensing, Gavin D Clark (gavin.clark@cn-bio.com) or call +44(0)1865 309 600.

About CN Bio Innovations

CN Bio Innovations, formerly Zyoxel Ltd, is part of Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human biomimetic platforms for the testing and development of therapeutics for serious human diseases, including Hepatitis B and C. Working closely with academic pioneers in the bio-engineering field, CN Bio is developing next generation tissue and disease models which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market.

About BioPark

Located close to the heart of London's biomedical technology community, BioPark provides specialist facilities and support for bioscience and health technology businesses, encouraging growth and the development of new products and technologies. Managed by Exemplas on behalf of the University of Hertfordshire and developed with funding from the East of England Development Agency (EEDA), BioPark is a thriving scientific

PRESS RELEASE

community of biopharmaceutical, contract research, medical technology and other biomedical businesses together with specialist service providers, forming a key element of the 'South Hertfordshire BioCluster'. - See more at: <http://www.biopark.co.uk/>

Enquiries

Emma Sceats, *Chief Operating Officer*
Gavin D Clark, *Director of Licensing*

E: emma.sceats@cn-bio.com

E: gavin.clark@cn-bio.com

W: www.cn-bio.com

T: +44-(0) 1865-309-600